Phase 2 N=21 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=130 A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
Diabetic Kidney Disease
Primary: Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24 — 1.12; 0.87; 0.85; 0.91 milligram/gram (mg/g)
Phase 2 N=22 Hydroxyproline Influence on Oxalate Metabolism
Hyperoxaluria
Primary: Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) — 12.8; 32.9; 14.8 percent converted
Phase 3 N=1,445 Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease, Autosomal Dominant
Primary: Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 — 2.777; 5.608 Percentage change per year — p=<0.0001
Phase 4 N=84 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures
Vertebral Compression Fracture
Primary: Comparison of 3 Month ODI Score Between Unipedicular and Bipedicular Kyphoplasty Groups — 15; 14 units on a scale — p=0.85
Phase 3 N=398 Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking · Pulmonary Disease, Chronic Obstructive · Tobacco Use Disorder
Primary: Smoking Abstinence (Point Prevalent) — 23; 24 Participants — p=0.88
N/A N=452 Use of Capnography in EGD and Colonoscopy With Moderate Sedation.
Hypoxia · Apnea · Hypotension
Primary: Number of Participants Experiencing Hypoxia During Capnography Monitoring. — 54; 59; 61; 63 Participants
Phase 2 N=74 Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Recurrent Fallopian Tube Cancer · Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer
Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants
Phase 2 N=197 A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Painful Diabetic Neuropathy · Diabetes
Primary: Summary of Neuropathic Pain Symptom Inventory (NPSI) — 34.44 units on a scale
Phase 2 N=500 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Breast Cancer · Menopausal Symptoms
Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL
Phase 3 N=240 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 98.9; 100.0; 89.1; 95.2 Percentage of Participants
N/A N=83 Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
Acute Respiratory Distress Syndrome · Shock · Ventilatory Failure
Primary: Need for Endotracheal Intubation — 24; 8 Participants
Phase 3 N=120 Pediatric Tonsillectomy Pain Reduction Study
Postoperative Pain
Primary: Total Number of Post-operative Doses of Analgesics. — 12; 12; 14 number of doses
Phase 4 N=27 Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
HIV · AIDS · Sleep Disorders
Primary: Percentage of Patients With Viral Loads < 50 Following the Switch — 20 Participants
Phase 2 N=248 Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Asthma
Primary: Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 — 0.284; 0.261; 0.252; 0.237 Liter